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Although nowadays cardiopulmonary bypass (CPB) can be considered safe, the
inflammatory response and bleeding diathesis are sti l l  major drawbacks of CpB. In
concert with the latter, this thesis is concerned with the affected haemostasis during
CPB. Bleeding during CPB originates primarily from rhe surgical f ield by oozing
from the capil laries. Although many causes are held responsible to some degree, most
researchers agree that platelet dysfunction during CPB most l ikely is the main cause
for the observed bleeding diathesis. The bleeding causes in many cases demand for
donor blood, emphasising the need for preservation of haemostasis. Moreover,
application of arterial instead of venous grafts for coronary artery bypass grafting and
increasing usage of aspirin by cardiac patients amplify blood loss and increase the
consecutive demand Íbr homologous blood products after cardiac surgery.
This thesis, therefore, is focused especially on factors and circumstances
during cPB which interfere with an adequate platelet function and, consequently,
affect haemostasis.
Based on l iterature and observations in previous studies reviewed in chapter 2,
reversible impairment of platelet function during CPB was hypothesised. This
dysfunction is characterised by a temporary loss of glycoprotein Ib receptors (GpIb),
the binding site fbr von wil lebrand factor and essential to the first phase of
haemostasis. The aim of this thesis in chapter l, therefore, was to demonstrate a
general mechanism responsible for the observed bleeding diathesis and platelet
dysfunction during CPB, and to develop techniques to decrease the bleeding diathesis.
All this was handled in several consecutive studies.
In Chapter 3 the factors and activation patterns in blood collected during
cPB, which are suspected to be related with the observed platelet dysfunctron, were
described. By analysis of samples from the circulating blood ancl from wound blood
collected in the pericardial cavity during the operation, highly activated clotting and
fibrinolysis in the wound blood compared to the circulating blood was demonsrrated.
Especially thrombin/antithrombin III complex (TAT), soluble fibrin and fibrinolytic
degradation products (FDP) were much higher in pericardial blood. once the
pericardial blood was returned to the systemic irculation, TATand FDPconcentrations
increased significantly also in the systemic blood. The effects of pericardial t issue to
activation of clotting and fibrinolysis was also demonstrated in vitro. Inhibit ion of
thrombin activity (clotting) by the introduction of hirudin during these tests, also
decreased the activation of f ibrinolysis, demonstrating that f ibrin products produced
by activation of the clotting system init iated fibrinolysis. The results of the study
strongly suggest that t issue dependent activation ofclotting by the pericardial t issue
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highly contributes to the systernic activation of f ibrinolysis, thus afÍècting haemostasis
during CPB.
For obtaining more defined data on wound blood and its possible effects on
circuiating blood after retranslusion, the effect of retransfusing postoperative shed
blood was determined. In Chapter 4, significant correlations between concentrations
of f ibrinogcn degradation products and soluble fibrin in shed blood and higher
postoperative blood loss were observed. Furthermore, retransÍÏsion of shed blood
significantly increased the total postoperative blood loss by 43 Vc (925 vs. 1320 ml).
Based on thesc clinical observations. an increased bleeding tendency related to
renewed fibrinolysis was hypothesised.
In the second part of this chapter concentrations t-PA and soluble fibrin similar to
those observed uring CPB were introduced to platelet rich plasma. The effect of this
treatment on platelet function rvas determincd by a platelet agglutination test
dependent  on von Wi l lcbrand factoÍ  (vWF) and GPIb reccptors ( r is tocet in
agglutination). T-PA and solublc fibrin together induced severe platclct damage,
resulting in a decreased ristocetin agglutination response. Thcrefbre, a plasmin
mediated platelet dysfunction during CPB was proposed, dependent upon factors
such as fibrin monomers and t-PA.
For assessrr.rcnt of plasmin gcncration in the prcsence of platelcts. in Chapter 5
a spectrophotornetric method was customised for monitoring plasmin generation in
mixtures which contain both plasnrinogen activiitors and platclcts. This kinetic model
allowed asscssment of syncrgistic efÍ 'ects ol 'platelets and fibrin monomers on
plasminogen activation. By kinetic analysis of the turnover of a plasmin specific
chromogenic substrate, a valuc fbr plasmin generation was establishcd. Gelfitered
plateiets alone. or in the prescncc of f ibrin monorncrs, mediated no plasminogen
activation. Howcver, increasing activation of plasminogen by incrcasing amounts of
platelets was found in the presence of t-PA and fibrin monomers. Thc obtained data
suggest that platelets offer an appropriate surÍi ice for t-PA/fibrin monomers to
activate plasminogen.
The method was applied in Chapter 6. in rvhich plasminogcn activation and
receptor darnagc of platelets by thc combined trcatment of t-PA and fibrin monomers
were measurcd and correlatcd. Also, the question was addressecl whcther this platelet
dysfunction in vitro could be prevented pharmacologically, as suggestcd by thc blood
saving efÍ-ects of Í ibrinolysis inhibitors during scvcral clinical intcrventions. In this
study the binding of soluble fibrin to the platelet surface was demonstrated. Platelets
pretreated with fibrin monomers or platelets in a mixture with fibrin monomers, t-PA
and plasminogen caused a significantly increased plasmin generation, dependent on
t-PA, fibrin monomers and platelets in a dose dependent fashion. The plasmin






































complexes. Since high concentrations of fibrin monomers and elevated levels of t-PA
were observedduring CPB, plasmin activity directedtowards membrane glycoproteins
essential for an adequate haemostasis was anticipated. Especially the downregulation
of GPIb/IX complexes would affect haemostasis and increase bleeding during and
after CPB.
Finally, it was demonstrated that inhibitors of fibrinolysis, such as cr"-antiplasmin,
tranexamic acid and aprotinin, can inhibit any generated plasmin activity in the fluid
phase. Aprotinin also prevented ownregulation of platelet GPIb/IX complexes, but
o,r-antiplasmin and tranexamic acid could not. This might explain the success of
aprotinin in preserving platelet function and preventing bleeding after CPB.
The developed hypothesis that wound blood from the thoracic cavity induces
fibrinolysis and consequently platelet dysfunction during CPB, was challenged by
changing the operation protocol in a controlled prospective clinical study, as presented
in Chapter 7. In this study thoracic wound blood was collected separately. The
wound blood was then retransfused to the patient at the end of operation, or was
retained. The immediate and significant increase of circulating concentrations TAT,
t-PA, FbDP and free plasma haemoglobin after retransfusion of wound blood
demonstrated the retransfusion effect. Moreover, the increased concentrations of
TAT and FbDP indicated renewed systemic lotting and fibrinolysis as a direct result
of the retransfusion of wound blood. Concentrations of all indicators mentioned
remained significantly lower in the retainment group.
The clinical data showed that retainment of thoracic wound blood resulted in
significantly decreased postoperative blood loss (822 ml in the retransfusion group
vs. 61 I ml in the retainment group, p<0.05 ) and similar or even reduced consumption
ofblood products such as red blood cell concentrates and single donor plasma. It was
concluded that retransfusion of highly activated wound blood during CPB affects
haemostasis and enhances wound bleedins.
In conclusion this thesis demonstrates that the observed concentrations ofclotting
and fibrinolytic factors, such as soluble fibrin and t-PA, can induce fibrinolysis
directed especially towards platelets. This mechanism is mediated by binding of
fibrin monomers, t-PA and plasminogen to the platelet surface. The consequently
generated plasmin wil l affect platelet glycoprotein Ib/lX expression and cause a
transient platelet dysfunction. Retransfused wound blood is therefore identiÍ jed as
the main cause of impairment of haemostasis.
One of the implications of the findings in the thesis concerns biocompatibil i ty
assessment of the extracorporeal circuits, and is described in Chapter 8.
Biocompatibil i ty assessment and related haematologic eÍïects of extracorporeal
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circuits during cardiopulmonary bypass will be greatly influenced when other
substantial blood activating mechanisms are manifest. The large changes in circulating
concentrations of activated products, caused by the retransfusion ofthoracic wound
blood, will obscure effects induced by the extracorporeal circuit. In this clinical study
it was demonstrated that some variables are unfit for characterisation of extracorporeal
circuit biocompatibil i ty. Moreover, assessment of extracorporeal circuit
biocompatibility is only feasible when thoracic wound blood is retained, or washed
before retransfusion.
A summary and general conclusions of the thesis are presented in Chapter 9
(English) and Chapter 10 (Dutch).
Some general background on the components and mechanism of haemostasis is
provided in Addendum I of this thesis. A model for the mechanism of aprotinin
(Trasylol@) related preservation of peri- and postoperative haemostasis during CPB,
in l ine with the findings of this thesis, is proposed in Addendum II.
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